Imatinib is a substrate for various multidrug resistance proteins

Neoplasma

Volumn 56, Issue 3, 2009, Pages 202-207

  Czyzewski, K ^a   Styczynski, J ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Chronic myeloid leukemia; Imatinib; LRP; MRP1; Multidrug resistance proteins; PGP

Indexed keywords

BUSULFAN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IMATINIB; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RHODAMINE 123; RIBONUCLEOPROTEIN;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; CELL STRAIN K 562; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; DAUNORUBICIN; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PIPERAZINES; PYRIMIDINES; RHODAMINE 123; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 67650312033     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_03_202     Document Type: Article

References (26)

1. Huntly BJ, Guilhot F, Reid AG et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205-2212. doi:10.1182/blood-2002-09-2763 (Pubitemid 37122400)
2. Ferrari G, Pastorelli R, Buchini F et al. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. J Proteome Res 2007; 6: 367-375. doi:10.1021/pr0603708 (Pubitemid 46173688)
3. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8: 1018-1029. doi:10.1016/S1470-2045(07) 70342-X (Pubitemid 47629897)
4. O'Dwyer ME, Druker BJ. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol 2000; 1: 207-211. doi:10.1016/ S1470-2045(00)00149-152
5. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373. doi:10.1182/ blood.V101.6.2368 (Pubitemid 36304670)
6. O'Brien SG, Guilhot F, Larson RA et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004. doi:10.1056/NEJMoa022457 (Pubitemid 36302244)
7. Baccarani M, Saglio G, Goldman J et al. European Leukemia- Net. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108: 1809-1820. doi:10.1182/blood-2006-02-005686
8. Litzow MR. Imatinib resistance. Arch Pathol Lab Med 2006; 130: 669-679.
9. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196. doi:10.1038/sj.leu.2402741 (Pubitemid 35331833)
10. Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000; 92: 1641-1650. doi:10.1093/jnci/92.20.1641 (Pubitemid 30807644)
11. le Coutre P, Kreuzer KA, Na IK et al. Determination of alpha-1 acid glycoprotein in patients with Ph1 chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85. doi:10.1006/bcmd.2002.0493
12. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745. doi:10.1182/ blood-2003-12-4276 (Pubitemid 39564452)
13. Illmer T, Schaich M, Platzbecker u et al. P-glycoprotein- mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408. doi:10.1038/sj.leu.2403257
14. Styczynski J, Wysocki M, Debski R et al. In vitro sensitivity of leucemic cells to nucleoside derivates in childhood acute leukemia: good activity In leukemic relapses. Neoplasma, 2005; 52: 74-78.
15. Styczynski J, Wysocki M, Debski R et al. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia. Acta Biochim Pol 2002; 49: 99-107. (Pubitemid 135688010)
16. Lee SM, Bae JH, Kim MJ et al. Bcr-Abl-Independent imatinib- resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase Inhibitors. J Pharmacol Exp Ther 2007; 322: 1084-1092. doi:10.1124/ jpet.107.124461
17. Hegedus T, Orfi L, Seprodi A, et al. Interaction of tyrosine kinase inhibitorswith the human multidrug transporter proteins, MDR1 and ABCC1. Biochim Biophys Acta 2002; 1587:318-325. (Pubitemid 34655800)
18. Che XF, Nakajima Y, Sumizawa T et al. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. Cancer Lett 2002; 187: 111-119. doi:10.1016/S0304-3835(02)00359-2 (Pubitemid 35279339)
19. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373. doi:10.1182/blood.V101.6.2368 (Pubitemid 36304670)
20. Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drugpumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004; 3: 1502-1505. (Pubitemid 40521401)
21. Ferrao PT, Frost MJ, Siah SP, Ashman LK. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102: 4499-4503. doi:10.1182/blood-2003- 01-0083
22. Lange T, Gunther C, Kohler T et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003; 101: 2152-2155. doi:10.1182/blood-2002- 05-1366 (Pubitemid 36302051)
23. Styczynski J, Wysocki M, Debski R et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia J Cancer Res Clin Oncol 2007; 133: 875-893. doi:10.1007/ s00432-007-0274-281
24. Qadir M, O'Loughlin KL, Fricke SM et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005; 11: 2320-2326. doi:10.1158/1078-0432. CCR-04-1725 (Pubitemid 40490193)
25. Legrand O, Simonin G, Beauchamp-Nicoud A et al. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999; 94: 1046-1056. (Pubitemid 29361837)
26. Ferrao PT, Frost MJ, Siah SP, Ashman LK. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102: 4499-4503. doi:10.1182/blood-2003- 01-0083